Alps Group

Alps Group Forward P/E

The Forward P/E Ratio of Alps Group (ALPS) as of Oct 20, 2026 is -171.76. In the previous year, Forward P/E Ratio was 127.29 — a change of -234.93% (lower).

Forward P/E

-171.76

YoY

-234.93%

Last updated:

Forward P/E Ratio of Alps Group is 2024 -171.76 . Forward P/E Ratio of Alps Group was 2023 127.29 . It decreases by -234.93% lower compared to the previous year.

The Alps Group Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2022
749.62 USD
Jan 1, 2023
127.29 USD
Jan 1, 2024
-171.76 USD
The Alps Group Forward P/E history
YEARForward P/EYoY
-171.76-234.93%
127.29-83.02%
749.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alps Group Stock analysis

What does Alps Group do? Alps Group Inc generates revenue through its integrated biotechnology platform Alps Life Sciences Inc., which offers advanced therapies and healthcare solutions. The company provides medical services, wellness solutions, and aesthetic treatments including non-surgical and surgical aesthetic services. Alps Life Sciences Inc. develops and commercializes therapies such as MyImmune (NK cells), CAR-T cells, and diabetes therapeutics, alongside research in mRNA vaccine technology and stem cell advancements like iPSCs. The firm operates molecular and cGMP laboratories for research and cultivation of cell and gene therapies. Alps Group Inc. targets global healthcare providers and patients seeking advanced medical solutions. Its biotechnology pipeline covers diverse areas including cancer therapies, infectious disease treatments, and regenerative medicine. The company's integrated ecosystem combines research, development, medical services, and wellness solutions to improve healthcare outcomes. The firm's aesthetic services cater to individuals seeking cosmetic and wellness procedures, while its medical services address broader healthcare needs. The company's revenue streams include the sale of medical services, wellness solutions, and aesthetic treatments. Alps Life Sciences Inc. focuses on developing therapies for specific health conditions such as diabetes and cancer, with a pipeline that includes mRNA-based vaccines and cell therapies. The molecular and cGMP laboratories support the development and production of these advanced therapies, contributing to the company's product offerings. Alps Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alps Group stock

Forward P/E Ratio of Alps Group is -171.76 in 2024.

Forward P/E Ratio of Alps Group changed from 127.29 to -171.76, representing a -234.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Alps Group since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Alps Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alps Group

All Key Metrics — Alps Group